Insider Transactions in Q1 2024 at Macrogenics Inc (MGNX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,625
-68.81%
|
$412,125
$21.5 P/Share
|
|
Mar 06
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
19,625
+29.48%
|
$196,250
$10.83 P/Share
|
|
Mar 04
2024
|
Eric Blasius Risser Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
41,159
-29.47%
|
$782,021
$19.82 P/Share
|
|
Mar 04
2024
|
Eric Blasius Risser Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+15.78%
|
$150,000
$10.15 P/Share
|
|
Mar 04
2024
|
James Karrels SVP, CFO and Secretary |
SELL
Open market or private sale
|
Direct |
30,000
-14.89%
|
$600,000
$20.5 P/Share
|
|
Mar 04
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
SELL
Open market or private sale
|
Direct |
10,000
-54.6%
|
$200,000
$20.0 P/Share
|
|
Mar 04
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+35.32%
|
$110,000
$11.5 P/Share
|
|
Feb 26
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
16,124
-64.45%
|
$274,108
$17.22 P/Share
|
|
Feb 22
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,366
-8.49%
|
$159,222
$17.11 P/Share
|
|
Feb 22
2024
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
28,125
+20.32%
|
-
|
|
Feb 22
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
10,126
-28.81%
|
$172,142
$17.11 P/Share
|
|
Feb 22
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
26,250
+42.76%
|
-
|
|
Feb 15
2024
|
Stephen L. Eck Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,872
-41.22%
|
$116,824
$17.4 P/Share
|
|
Feb 15
2024
|
Stephen L. Eck Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+50.0%
|
-
|
|
Feb 15
2024
|
Lynn Cilinski VP, Controller and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,378
-27.68%
|
$40,426
$17.4 P/Share
|
|
Feb 15
2024
|
Lynn Cilinski VP, Controller and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,668
+43.7%
|
-
|
|
Feb 15
2024
|
Scott Koenig President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,349
-1.31%
|
$243,933
$17.4 P/Share
|
|
Feb 15
2024
|
Scott Koenig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,341
+3.73%
|
-
|
|
Feb 15
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,441
-33.3%
|
$75,497
$17.4 P/Share
|
|
Feb 15
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
13,336
+50.0%
|
-
|
|
Feb 15
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,871
-6.67%
|
$99,807
$17.4 P/Share
|
|
Feb 15
2024
|
Ezio Bonvini Sr VP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+15.93%
|
-
|
|
Feb 15
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
5,020
-37.64%
|
$85,340
$17.4 P/Share
|
|
Feb 15
2024
|
Thomas Spitznagel Sr VP, Technical Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
13,336
+50.0%
|
-
|
|
Feb 15
2024
|
James Karrels SVP, CFO and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,327
-2.58%
|
$90,559
$17.4 P/Share
|
|
Feb 15
2024
|
James Karrels SVP, CFO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
15,003
+6.76%
|
-
|
|
Feb 15
2024
|
Eric Blasius Risser Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,879
-8.29%
|
$99,943
$17.4 P/Share
|
|
Feb 15
2024
|
Eric Blasius Risser Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+19.03%
|
-
|
|
Feb 07
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,334
-4.47%
|
$60,012
$18.0 P/Share
|
|
Feb 05
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
SELL
Open market or private sale
|
Direct |
76,251
-85.66%
|
$1,220,016
$16.5 P/Share
|
|
Feb 05
2024
|
Jeffrey Stuart Peters Senior VP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
76,251
+36.15%
|
$762,510
$10.83 P/Share
|
|
Feb 01
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,316
-15.13%
|
$199,740
$15.0 P/Share
|
|
Jan 19
2024
|
Ezio Bonvini Sr VP, Research & CSO |
SELL
Open market or private sale
|
Direct |
13,316
-13.15%
|
$159,792
$12.0 P/Share
|